To assess the possible effects of MSCs on prostate cancer cells, we isolated mouse bone MSCs (CD29+SCA1+CD45Neg) and confirmed their stemness properties by performing osteoblastic, adipogenic, and chondrogenic differentiation assays (Supplementary Fig. 2). Here, CASP3 is linked to prostate cancer.